This is another article in my continuing commentary on market access and politics. The focus in this case is to look more closely at behaviours of people involved from government, industry and healthcare. Occupying these roles are people who bring… Read More »Behavioural economics: payer psychology and market access
This article is a continuation of my commentary on the politics of healthcare with particular focus on issues that likely interest those involved in market access and government relations. In this case, I’m commenting on government and market failure in… Read More »Market and government failure: market access politics
Market access is wrapped in the politics of health The attention politicians and stakeholders pay to healthcare and its challenges is a keen driver of the ease or difficulty companies experience with drug regulation and market access and has implications… Read More »The politics of market access
We are in a new world when it comes to access to and the use of data and evidence. Real world data and evidence takes us from structured studies to the routine delivery of healthcare, actual use of a medicine,… Read More »Real world data and evidence in healthcare: The market access challenge
The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in… Read More »Positioning drugs in markets: how payers determine value
How can I be sure the medicine I take is genuine? Counterfeit medicines are a global problem, with trade in the billions of dollars. The World Health Organization estimates 8-10% of all drugs supplied globally are counterfeit. Counterfeits are a… Read More »Smart anti-counterfeiting: it is all in the system’s design
Continuing the theme of looking at life sciences, healthcare implications for the UK exiting the EU. The NHS, the UK’s public healthcare system, procures medicines in many cases through the benefits of the single market. While it is not clear… Read More »“I told you so”: post-Brexit access to medicines and medical device technologies
Sir Andrew Dillon, the erstwhile leader of NICE as said that it is irrational for the Cancer Drug Fund to pay for drugs that NICE has turned down. He’s right of course, it is irrational but is it wrong? The… Read More »Broken logic: NICE and the Rule of Rescue